Bimekizumab for Moderate-to-severe Plaque Psoriasis Bimekizumab for Moderate-to-severe Plaque Psoriasis

Bimekizumab, which selectively inhibits both interleukin-17A and IL-17F, is currently under investigation for treatment of moderate-to-severe psoriasis. What is the best dosing interval?The British Journal of Dermatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news